Pharmacy Drugs
Recent Posts
- Sinovac Files Clinical Trial Application With SFDA For Vaccine Against Hand, Foot, And Mouth Disease
- MRI Injury Prompts Recall of Medical Blanket
- FDA Okayed Cardiac Devices on Weak Evidence, Researchers Charge (CME/CE, with audio)
- FDA, Health Plans Begin Study of Drug Effects in Pregnancy
- No New Year's Joy from FDA
Random Posts
- Report Finds Racial Disparities In Prescription Drug Access, Use, Regimen Adherence
- FDA Okays IV Agent to Replace Iron in Chronic Kidney Disease
- Tekmira Pharmaceuticals Initiates ApoB SNALP Phase 1 Clinical Trial
- Pharmacy Bodies Call For Reinstatement Of Community Pharmacists To The Shortage Occupations List, UK
- Cook Completes Patient Enrollment In REFORM Clinical Trial
- Study Uncovers How Tiny Levels Of Carbon Monoxide Damage Fetal Brain
- Antigenics' QS-21 Adjuvant Enters Pivotal Phase 3 Clinical Trial Of GlaxoSmithKline's Malaria Vaccine
- TCGRx Launches The C-Ray Automatic Pill Counting Device In The Retail Pharmacy Market
- Promising Robotic Therapy For Cerebral Palsy
- Néovacs To Expand Clinical Testing Of Its TNF-alpha Kinoid Lead Product Candidate Following Positive Preliminary Findings From A Phase I/II Study
Versartis Presents Preclinical Data For Novel Type 2 Diabetes Drug
Posted by: admin in Pharmacy Drugs on September 30th, 2009
Versartis, Inc. today presented preclinical data demonstrating the potential for monthly dosing of its lead product, VRS-859 (exenatide-XTEN), for the treatment of type 2 diabetes. The data were presented by Jeffrey Cleland, Ph.D., Founder and Chief Executive Officer of Versartis, at the IBC Protein Engineering & Design Conference in San Diego.
In his talk, “Half-life Extension and In Vivo Biological Activity of Peptide and Protein Therapeutics,” Dr. Cleland presented VRS-859 preclinical data in models of diabetes and pharmacokinetics in mice, rats, dogs and monkeys. Versartis has begun development activities for VRS-859 including manufacturing and regulatory meetings. A clinical study of VRS-859 in patients with type 2 diabetes is planned for the first half of 2010.
Versartis is also finalizing lead selection for VRS-317 (human growth hormone-XTEN), a monthly dosage form. Dr. Cleland presented preclinical proof of concept and pharmacokinetic data. Versartis plans to begin Phase I clinical trials of VRS-317 in patients with growth hormone deficiency in the second half of 2010.
In addition to the reduced dosing frequency, Versartis’ XTEN products enable room temperature stability and low cost manufacturing. The XTEN properties allow for co-formulation and co-administration of proteins and peptides that are normally incompatible. Versartis is conducting research on combination products for metabolic disease to exploit these novel properties.
“Versartis is focusing on treatments for metabolic and endocrine diseases that currently require daily or weekly dosing,” explained Dr. Cleland. “Our results to date demonstrate the potential for monthly dosing of our compounds. The potential for improved convenience along with other XTEN properties provide a distinct advantage for Versartis’ products over other products on the market or in development.”
Source
Versartis, Inc.
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.